News
Medicure Announces New AGGRASTAT'R' Data at 2006 Scientific Sessions of the American Heart Association
Medicure Inc., a cardiovascular focused biopharmaceutical company, today announced that new data comparing Single High-Dose Bolus AGGRASTAT® (tirofiban) versus ReoPro® (abciximab) in patients undergoing percutaneous coronary intervention (PCI) were presented today at the 2006 Scientific Sessions of the American Heart Association (AHA) in Chicago, Illinois. Medicure acquired the exclusive U.S. rights to AGGRASTAT®, a glycoprotein (GP) IIb/IIIa inhibitor, in August 2006.
Dr. Bart Dawson, from the Cardiovascular Medicine Division, University of Kentucky College of Medicine, presented results from a meta-analysis of 5 prospective randomized studies comparing Single High-Dose Bolus (25 mg/kg) tirofiban plus infusion with conventional abciximab regimen on the 30-day composite of death, myocardial infarction (MI) and target vessel revascularization (TVR), in 1392 patients undergoing PCI. The study results demonstrated an event rate for the 30-day composite of 6.1% with tirofiban and 7.3% with abciximab (p=0.46). There were no significant differences in major and minor bleeding and thrombocytopenia between the groups.
"This pooled analysis of existing data suggests that Single High-Dose Bolus tirofiban may be as effective as abciximab in patients undergoing PCI with a comparable safety profile," commented Dr. David Moliterno, Chief of Cardiovascular Medicine at the University of Kentucky and the study's senior author. "Given the substantial price difference between the two products, Single High-Dose Bolus tirofiban would be a cost effective alternative to abciximab for PCI patients."
About Medicure Inc.
Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. The Company's solid position in this field is highlighted by the following:
- Two drugs, MC-1 & MC-4232, in late stage clinical development
- Four positive Phase II trials completed with MC-1
- FDA Fast Track designation for MC-1
- U.S. rights to AGGRASTAT® Injection (tirofiban hydrochloride)
- Dual action antithrombotic, MC-45308, with positive preclinical results
Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.